Tourmaline (TRML, Financial) is witnessing increased interest in targeting IL-6-driven cardiovascular inflammation, a sentiment supported by dialogues with field experts, participation in significant medical gatherings, and continuous review of emerging scientific insights. The company, led by CEO and Co-Founder Sandeep Kulkarni, MD, is eager for the forthcoming release of topline results from its Phase 2 TRANQUILITY trial. This data presentation, expected later in the second quarter, could propel pacibekitug into the subsequent phase of development focused on atherosclerotic cardiovascular disease, abdominal aortic aneurysm, and possibly other related cardiovascular conditions.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 9 analysts, the average target price for Tourmaline Bio Inc (TRML, Financial) is $53.56 with a high estimate of $65.00 and a low estimate of $35.00. The average target implies an upside of 200.03% from the current price of $17.85. More detailed estimate data can be found on the Tourmaline Bio Inc (TRML) Forecast page.
Based on the consensus recommendation from 10 brokerage firms, Tourmaline Bio Inc's (TRML, Financial) average brokerage recommendation is currently 1.6, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
